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Abstract  
 
1g,25-dihydroxyvitamin D3 signals via the Vitamin D Receptor (VDR). Higher serum 
vitamin D is associated with thinner primary melanomas and better outcome, 
although a causal mechanism was not established. As melanoma patients commonly 
avoid sun exposure, and consequent vitamin D deficiency might worsen outcomes, 
we interrogated 703 primary melanoma transcriptomes to understand the role of 
vitamin D-VDR signalling and replicated the findings in TCGA metastases. VDR 
expression was independently protective for melanoma death in both primary and 
metastatic disease. High tumor VDR expression was associated with upregulation of 
pathways mediating anti-tumor immunity and correspondingly with higher imputed 
immune cell scores and histologically detected tumor infiltrating lymphocytes (TILs). 
High VDR expressing tumors had downregulation of proliferative pathways, notably 
Wnt/d-catenin signaling. Deleterious low VDR levels resulted from promoter 
methylation and gene deletion in metastases. Vitamin D deficiency (< 25 nmol/l ~ 10 
ng/ml) shortened survival in primary melanoma in a VDR-dependent manner. In vitro 
functional validation studies showed that elevated vitamin D-VDR signaling inhibited 
Wnt/d-catenin signaling genes. Murine melanoma cells overexpressing VDR 
produced fewer pulmonary metastases than controls in tail vein metastasis assays. 
Vitamin D-VDR signaling contributes to controlling pro-
proliferative/immunosuppresive Wnt/d-catenin signaling in melanoma and this is 
associated with less metastatic disease and stronger host immune responses. We 
report this as evidence of a causal relationship between vitamin D-VDR signaling 
and melanoma survival which should be explored as a therapeutic target in primary 
resistance to checkpoint blockade.  
 
Statement of significance 
 
This study highlights that the prognostic significance of vitamin D-VDR signaling in 
melanoma is associated with inhibition of Wnt/beta-catenin mediated tumour 
proliferation as well as enhanced anti-tumor host immune response.
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Introduction 
 
1g,25-dihydroxyvitamin D3 is the ligand for the dimeric vitamin D receptor (VDR) and 
retinoid X receptor (RXR): ligand-receptor binding facilitates transcription of target 
genes containing the vitamin D response element (VDRE) (1). The physiological 
effect of the vitamin D-VDR signaling axis is often target tissue-specific (2). 
The association of low serum 25-hydroxyvitamin D2/3 levels (henceforth 
referred to as vitamin D) with higher cancer incidence has been reported (3) but the 
significance of the association has been debated (4). Extensive in vitro evidence 
however indicates an anti-proliferative role of vitamin D, with 1,25(OH)2 vitamin D3 
treatment shown to induce expression of pro-apoptotic genes and anti-proliferative 
genes in prostate (5), breast (6), colon (7) squamous cell carcinoma and leukaemia 
cells (8, 9).  
We have previously reported that higher serum vitamin D levels at recruitment 
were associated with lower AJCC stage and better melanoma specific survival 
(MSS) in the Leeds Melanoma Cohort (LMC) (10). This was subsequently verified in 
5 additional studies (11-15), which collectively indicate a significant role for vitamin 
D-VDR signaling in melanoma progression. 
The unique dataset used in this study was derived from 703 formalin-fixed 
paraffin-embedded (FFPE) primary melanomas, from the LMC, a population-based 
and extensively annotated cohort with a long follow-up (10). Tumor-derived 
transcriptomic data, clinical, histopathological and whole-genome copy number 
alteration (CNA) data were jointly analysed to assess the pan-genome effects of 
vitamin D-VDR signaling and to determine the processes most associated with this 
pathway. Importantly, these findings were replicated in TCGA metastatic melanomas 
and then functionally validated using in vitro and in vivo experiments. 
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Materials and methods 
 
The Leeds Melanoma Cohort (LMC) tumor transcriptome 
LMC tumor transcriptome processing was described previously (16)(accession no. 
EGAS00001002922). Briefly, tumor samples were taken from formalin fixed paraffin 
embedded (FFPE) primary melanomas and RNA was extracted to generate whole 
genome gene expression data (Illumina DASL HT12.4 array). Background correction 
and quantile normalisation were applied; singular value decomposition was used to 
assess the confounding factors which were subsequently adjusted out. Participants 
in the LMC gave written informed consent; the study was conducted in accordance 
to international ethical guidelines (Declaration of Helsinki) and was approved by the 
national ethics committee (MREC 1/03/57 and PIAG3-09(d)/2003). 
 
Measurement of serum vitamin D at diagnosis 
For 554 of the 703 participants with transcriptomic data, 25-hydroxyvitamin vitamin 
D2 and D3 (nmol/L) was measured as described previously (10) and adjusted for 
season (see Supplementary Methods). 
 
TCGA melanoma dataset 
TCGA metastatic melanoma data (n=365 samples) such as transcriptomic (RNA-
Seq), clinical, methylation and copy number data were downloaded from cBioPortal 
(http://www.cbioportal.org/). The same statistical tests and software/packages were 
used to analyse Leeds and TCGA data. 
 
Statistical analyses 
Association of VDR expression with clinical variables: univariate and multivariate 
linear regression were used to test the association between VDR and AJCC stage, 
mitotic number, tumor site, age and sex.  
Association of VDR expression with MSS: univariate and multivariate Cox 
proportional hazards models were used to test the prognostic effect of VDR 
expression level after adjusting for AJCC stage (7th Edition), tumor mitotic number, 
tumor site and TILs. For this analysis VDR expression was on the continuous log2 
scale, meaning that Hazard Ratio (HR) per VDR unit corresponds to change in 
hazard when expression is doubled. 
 5 
 
VDR copy number changes in the LMC tumors 
 
Copy number profiles were estimated from NGS output from sequenced DNA 
samples from a subset of LMC tumors (n=276, 39%) as described (17). Gistic2.0 
was used to identify VDR copy number estimates (see Supplementary Methods). 
 
Whole-transcriptome correlation with VDR 
Linear regression analysis and Benjamini-Hochberg multiple testing correction (False 
Discovery Rate- FDR) was used to test the correlation between the expression of 
each gene and VDR in the tumors. Genes with FDR<0.05 and |Reg Coef|>0.2 (Reg 
Coef- Regression coefficient) were plotted in a volcano plot (R function: ‘plot’) and 
used for functional enrichment analysis.  
Since VDR is expressed by keratinocytes (18), a FLG2-adjusted whole-
transcriptome correlation with VDR was additionally performed (Fillagrin family 
member 2: FLG2 being a maker of keratinocyte differentiation). This sensitivity 
analysis was conducted to account for any bias in VDR expression which might have 
originated from keratin-rich melanoma subsets, which have been previously reported 
(19-21).   
 
Functional enrichment analyses  
The ‘Gene set/mutation analysis’ feature of ReactomeFIViz (22) was used to identify 
significantly enriched pathways (Benjamini-Hochberg FDR <0.05, from 
hypergeometric test)  from a given input gene list. 
 
VDR-binding regions 
The genomic regions identified as having VDR-binding peaks across 6 tissue types 
(23) were downloaded as BED files. Additionally, genomic regions known to contain 
the VDR-binding motif were downloaded from Motifmap (as BED files). In both 
cases, genes associated with genomic regions were identified using GREAT 3.0.0 
(24): ‘Basal plus extension’ approach was used with Human GRCh37 assembly, 
whole genome as background regions and the gene regulatory domain set to +20 kb 
upstream and +400 kb distal. The genes which mapped to these regions (‘region-
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gene associations’) were exported and their overlap with VDR-correlated genes in 
the LMC (at FDR<0.05) was assessed.  
 
VDR expression across Lund and TCGA molecular phenotypes 
Nearest centroid method (21) was used to classify the LMC tumors into TCGA and 
Lund molecular melanoma phenotypes (see Supplementary Methods). Differential 
VDR expression across these subgroups was tested with the Mann-Whitney test. 
 
Imputed Immune scores 
As described by Pozniak et al (25). Briefly, 28 immune cell scores were calculated as 
mean expression of genes pertaining to an immune cell type, after deducting genes 
identified as potentially non-immune cell specific, from the initial immune gene 
signature described by Angelova et al. Correlation analysis of each immune cell 
score with VDR expression was conducted.  
 
Expression of VDR and response to checkpoint blockade 
VDR expression was compared between responders and non-responders in two 
published albeit small transcriptomic data sets: i) 38 patients treated with PD-1 
blockade (26) and ii) 40 patients treated with CTLA4 blockade (27). Both studies 
used pretreatment biopsies. Fold change was computed as ratio of mean VDR 
expression in responders to non-responders 
 
Vitamin D-VDR subgroup analysis 
X-tile (28) was used to identify patient subgroups with the most contrasted survival 
profiles (melanoma-specific) based on their tumor VDR expression in the LMC. This 
approach was trained in randomly selected 2/3 of the samples and validated in the 
remaining 1/3. The cut-points defining patient subgroups in terms of percentiles were 
applied to the TCGA metastatic melanoma dataset for replication.  
The identified VDR groups were further stratified based on participants’ serum 
vitamin D levels at recruitment (season-adjusted) in the LMC. Clinically defined 
vitamin D deficiency is generally considered to be <25 nmol/L (29), with recent 
evidence defining vitamin D deficiency able to compromise bone health as 
<30nmol/L (30). Thus, in the LMC dataset, serum vitamin D levels <25nmol/L and 
>25nmol/L were classified as ‘deficient’ and ‘sufficient’.  
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Vitamin D treatment of human melanoma cells 
SK-MEL-28 and MeWo cells (courtesy of Professor Alan Melcher, Leeds CRUK cell 
line bank) were authenticated using the PowerPlex 16 System (Promega, USA), 
cultured, treated with 1,25 (OH)2 vitamin D3 (Supplementary Methods), collected at 
different time points, RNA extracted and used to generate gene expression profiles 
(HG-U133 plus 2.0 array, Affymetrix). Genes differentially expressed in vitamin D-
treated versus control cells were identified at each time point (FDR<0.10) and were 
used for functional enrichment using Reactome FIViz.  
 
Generation of VDR-B16BL6 and control-B16BL6 cells  
B16BL6 cells (chosen owing to lowest endogenous VDR expression among B16 
strains, estimated from transcriptomic data by Dr Martin del Castillo- personal 
communication) were purchased from the M. D. Anderson Cancer Center Cell Line 
Core facility. Cells were screened for the presence of mycoplasma and mouse 
pathogens (at Charles River Laboratories, USA) before culturing. Early passage 
B16BL6 cells were cultured and transfected with murine VDR cDNA (synthesised by 
GeneArtTM) or empty backbone plasmid to generate the VDR-B16BL6 (clones V1, 
V2) and control-B16BL6 (clones C1, C2) cells respectively (Supplementary 
Methods), verified by Western blot and qRT-PCR.  
 
In vivo tail-vein metastasis assay 
 
Though subcutaneous B16 models have bene used to demonstrate the role of NK 
cells in host responses to melanoma, we adopted the tail-vein model based on 
successful demonstration by the group of a role for effector T-cells and NK cells in 
B16 pulmonary metastases studies (31) and other reports of a role for T-cells in B16 
melanoma cells (32-34). The care and use of all mice in this study were in 
accordance with the UK Animals in Science Regulation Unit’s Code of Practice for 
the Housing and Care of Animals Bred, or Used for Scientific Purposes, the Animals 
(Scientific Procedures) Act 1986 Amendment Regulations 2012, and all procedures 
were performed under a UK Home Office Project license, which was reviewed and 
approved by the Sanger Institute’s Animal Welfare and Ethical Review Body. 
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Housing and husbandry conditions were as described previously (31) and mice were 
maintained on Mouse Breeders’ Diet (Laboratory Diets, 5021-3) throughout the 
study. V1, V2, C1 and C2 cells (detailed above) were tail-vein administered to 6-10 
week old sex-matched wildtype (C57BL/6NTac) mice (104 cells in 0.1mL PBS). After 
21 days, mice were humanely sacrificed and their lungs macroscopically examined 
to determine the number of metastatic deposits in all 5 lobes (‘met count’). Lungs 
were formalin fixed, processed and embedded in paraffin wax blocks, from which 
consecutive 5om sections were cut. and used for H&E and CD3 staining. H&E 
sections were digitally scanned (Leica Aperio AT2) and total metastatic area (‘met 
area’ om2) was calculated as the total area of all metastatic deposits, across all 5 
lung lobes using Aperio Imagescope (Leica Biosystems). CD3+ lymphocytes were 
estimated as described in Supplementary Methods. 
 
Wnt/d-catenin signaling in VDR-B16BL6 and control-B16BL6 cells 
 
cDNA from V1, V2, C1 and C2 cells were analysed using a RT-PCR array of 84 
mouse Wnt/d-catenin pathway genes (see Supplementary Methods). Relative 
expression was calculated using the Delta-Delta CT method, normalized to average 
Ct of the 5 housekeeping genes provided in the array. Fold change (FC) of the VDR-
B16BL6 clones relative to control-B16BL6 clones was calculated as follows: 
FCV1(or)V2= 2^(-FFCt)V1(or)V2 where FFCtV1(or)V2= FCtV1(or)V2-FCtavg(C1 & C2). 
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Results 
VDR expression is independently protective for melanoma death in the LMC 
primary and TCGA metastatic melanomas  
VDR expression was significantly lower in tumors of higher AJCC stage, higher 
mitotic rate and tumors on the trunk and sun protected sites (compared to tumors on 
the head) (Univariate analysis, Table 1) in the 703 LMC primaries. In multivariate 
analysis, lower VDR expression was independently associated with higher mitotic 
rate (P=0.001) and tumor site (P=0.001 for tumors of trunk compared to those on 
head), with borderline significance for higher stage (P<0.06) (Table 1).  
Higher tumor VDR expression was protective for melanoma death 
independent of stage, tumor mitotic rate, tumor site and histologically reported TILs 
(HR for melanoma death=0.80, P=0.008, Table 1). Though VDR expression 
correlated significantly with other members of the NR1lL family such as LXRB, 
FXR1, FXR2 and PXR expressions (Supplementary Table 1), it remained 
significantly prognostic after adjusting for the expression of those genes (adjusted 
HR for melanoma death=0.77, P=0.001). 
Since VDR forms heterodimers with RXR and RXRi signalling has been 
reported to drive epithelial/mesenchymal transition and invasion in melanoma, we 
tested the prognostic effect of the expression of genes coding for RXR receptors. In 
the LMC, VDR did not correlate significantly with RXRi (Supplementary Table 1) and 
the prognostic significance of VDR expression was independent of the expression of 
RXRc, RXRd and RXRi (adjusted HR for melanoma death=0.75, P=0.0001) 
Immunohistochemistry of LMC primary melanomas revealed that VDR 
expression was predominantly in tumor (rather than immune) cells  (representative 
image in Supplementary Figure 1, quantified in Supplementary Table 2). 
In the TCGA metastatic melanomas (n=353), higher VDR expression was 
protective for death (Overall survival HR=0.82, P=0.03).  
 
Tumor VDR expression is associated variably with CNAs and promoter 
methylation in primary and metastatic melanomas  
In the LMC primary melanomas, VDR expression showed a weak positive correlation 
with VDR copy number, which failed to reach statistical significance (P=0.12, Figure 
1A). However, in the TCGA metastatic melanomas, VDR expression was lowest in 
 10 
tumors with hemizygous deletion compared to those with ‘no changes/neutral’ 
(P=0.01) and was significantly higher in tumors with ‘gain’ (P=0.007) and ‘high-level 
amplifications’ (P<0.00001) (Figure 1B). VDR copy number was more frequently 
reduced in distant metastases compared to regional lymph node metastases 
(P=0.015, Figure 1C). Concomitantly, the TCGA data also showed progressively 
reduced VDR expression from primary to lymph node then distant metastases 
(Figure 1D). VDR expression was significantly and inversely correlated with VDR 
promoter methylation (P=0.0001, Figure 1E) in TCGA metastases.  
 
VDR correlates positively with genes enriched for immune-related pathways 
and negatively with proliferation-related pathways in LMC primary and TCGA 
metastases  
In the LMC, an agnostic whole-transcriptome correlation analysis identified genes 
positively (n=2025) and negatively (n=3408) correlated with VDR (Figure 2). The 
negatively correlated genes were enriched for proliferation-related pathways such as 
mitotic prometaphase, Wnt signaling, mitochondrial translation, TCA cycle, and 
cadherin signaling (Figure 2, Supplementary Table 3). By contrast, the positively 
correlated genes were enriched for immune-related pathways such as cytokine-
cytokine receptor interaction, TNF, IFNi, IL12-mediated, NFmB and chemokine 
signaling (Figure 2, Supplementary Table 4). VDR-correlated genes remained largely 
unchanged after FLG2-adjustment (Methods, Supplementary Table 5), indicating 
that confounding from epidermal sampling is unlikely.  
We assessed if the VDR-correlated genes in the LMC were known to have a 
VDR-binding site. Tuoresmaki et al. previously reported 54 non-overlapping genomic 
VDR-binding regions recurrent in 6 tissue types, based on meta-analysis of VDR 
ChIP-Seq data (23). We mapped the 54 genomic binding regions to be associated 
with 73 genes (GREAT, sMethods), of which 43 genes (58%) were among the 
significant VDR-correlated genes in the LMC. Alternatively, 60% of genes mapped to 
genomic regions containing the VDR-binding motif (identified by Motifmap, see 
Methods) also correlated significantly with VDR in the LMC.  
In the TCGA metastatic melanomas, VDR correlated negatively with genes 
enriched for: ECM organization, cadherin signaling, eukaryotic translation initiation, 
TGFd and VEGFR1 signaling; and positively with: NFmB, TNF, IFNc/d, IFNi, IL12-
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mediated, TCR and chemokine signaling in naïve CD4 T-cells pathways 
(Supplementary Tables 6 and 7). The majority overlapped with those observed in 
LMC primaries. 
 
Tumor VDR expression is associated with reported melanoma phenotypes, 
imputed immune cell scores and reduced Wnt/d-catenin signaling  
The LMC primaries were classified based on previously described melanoma 
molecular phenotypes (20, 35) (Supplementary Methods). The TCGA signature (20) 
classified the 703 LMC melanomas into Immune (n=192), Keratin (n=247) and MITF-
low (n=150) subtypes. VDR expression was significantly higher in the Keratin and 
Immune subtypes compared to the MITF-low subtype (P=1.1x10-6) (Figure 3A). The 
Lund signature (35) classified tumors into High-immune (n=173), Normal-like 
(n=198), Pigmentation (n=222) and Proliferative (n=83) subtypes. VDR expression 
was significantly higher in High-immune subtype compared to the poorer prognosis 
Proliferative (P= 7.5x10-8) and Pigmentation subtypes (P=6x10-13) (Figure 3B).  
VDR expression correlated positively with 25 of the 26 immune cell scores 
(Supplementary Table 8) of which the strongest correlation (Correlation 
coefficient>0.30) was with Dendritic cells, MDSCs, neutrophils, central memory CD4, 
NK, Th1, Th2 and T-cells (Figure 3C). Concordantly, VDR expression was 
significantly lower in tumors with ‘absent’ immune infiltrate compared to tumors with 
‘non-brisk’ (P=0.02) and ‘brisk’ immune infiltrate (P=0.004) (Figure 3D), according to 
histopathological scores which were available for 601 (86%) of the LMC melanomas. 
We previously reported an immunologically “cold” tumor subtype in the LMC 
(Consensus Immunome Cluster 4, CIC4) with increased d-catenin signaling, reduced 
imputed immune scores for cytotoxic, T cell and activated dendritic cells (aDC) and 
expression of genes coding for checkpoint molecules (16). VDR expression was 
lowest in that tumor subtype (Figure 3E), which was concordant with the agnostic 
correlation analysis identifying Wnt/d-catenin as the pathway most strongly 
associated with low immune signals in both LMC primary and TCGA metastatic 
melanomas.  
To compare VDR expression with response to immunotherapy, we used 
previously published therapy-response datasets (26, 36). VDR expression did not 
vary significantly between responders (n=15) and non-responders (n=13) to anti-PD-
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1 therapy (P=0.27), nor to anti-CTLA4 treatment (P=0.12) in a dataset of responders 
and (n=13) non-responders (n=22) (Supplementary Figure 2), although in the latter, 
VDR expression was 1.35 times higher in responders compared to non-responders 
(Fold Change= 1.35). 
 
Deficient levels of serum vitamin D are associated with more melanoma deaths 
within the context of VDR expression 
The 703 LMC primary melanomas were stratified into 3 groups using a survival-
based stratification approach (X-tile, see Methods). VDR expression thresholds 
which best predicted differential survival identified the following groups: 17% with the 
lowest VDR expression (low-VDR group, n=119), 17% of tumors with highest VDR 
expression (high-VDR group, n=119) and middle 66% (intermediate-VDR group, 
n=465) having the worst, best and intermediate survival respectively (P= 5.2x10-8, 
Figure 4A-B). This was replicated in the TCGA metastatic melanomas (n=353) using 
the same VDR expression percentiles (P=0.03, Figure 4C-D).  
Amongst the three VDR groups: deficient serum vitamin D levels (<25nmol/L) 
were associated with poorer prognosis compared to sufficient vitamin D levels 
(>25nmol/L) in the intermediate-VDR group (HR=1.73, P=0.02), but not in the low-
VDR (P=0.66) or high-VDR (P=0.55) groups (Figure 4E). The deleterious association 
with vitamin D deficiency was therefore apparent within the context of VDR 
expression. Intermediate-VDR group participants with deficient vitamin D were 
characterised by higher Breslow thickness (P=0.02), higher frequency of pathologist-
reported vascular invasion (P=0.01) and AJCC stage II tumors (compared to stage I: 
P=0.01), when compared to those with sufficient vitamin D. An agnostic whole-
transcriptome analysis identified no gene significantly differentially expressed (at 
FDR<0.10) between participants with deficient or sufficient vitamin D in the 
intermediate-VDR group. However, among the pathways that correlated significantly 
with VDR (Figure 2), the following were significantly underexpressed in participants 
with vitamin D sufficiency: NK cell mediated cell killing (P=0.02), IL12 (P=0.03) and 
TCR signaling on naïve CD4 and CD8 signaling (P=0.05).  
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Vitamin D treatment and increased VDR expression inhibit Wnt/d-catenin 
pathway and melanoma cell growth in vitro and in vivo 
We functionally validated our findings from the LMC primary and TCGA metastatic 
melanomas, where high VDR-expressing tumours (with active vitamin D-VDR 
signaling) had better survival and reduced expression of proliferative pathways, in 
particular the Wnt/d-catenin signaling. The human melanoma cell lines SK-MEL-28 
and MeWo treated with 1,25 (OH)2 vitamin D3 showed reduced proliferation post-
treatment (Figure 5A). At 24 and 48 hours post-treatment, VDR expression was 
significantly upregulated while Wnt signaling and ECM organization genes were 
among the top downregulated pathways in both cell lines. The pathways upregulated 
in both cell lines at both time points were: MAPK, IFNc/d, TGFd and TLR signaling 
(Figure 5B).  
In a second functional validation model, the in vivo metastatic potential of 
murine melanoma B16BL6 cells overexpressing VDR (“VDR-B16BL6 cells”) was 
compared to control cells expressing low/no VDR (“control-B16BL6 cells”) 
(Supplementary Figure 3). Mice injected with VDR-B16BL6 cells developed 
significantly lower pulmonary metastatic load (metastatic area and metastases 
count) compared to those dosed with control-B16BL6 cells (P<0.04), with 
comparable results from both clones in two independent experiments (pooled 
analyses from 2 experiments represented in Figure 5C). Differential expression of 
Wnt/d-catenin pathway genes between VDR-B16BL6 and control-B16BL6 was 
compared using a pre-formatted qRT-PCR-based array. Of the 84 Wnt/d-catenin 
genes tested, 62 genes had lower expression (fold change <1, of which 26 had fold 
change <0.5) in both VDR clones compared to control clones (Figure 5D). Twelve 
genes had increased expression (fold change>1, none with fold change>2) in both 
VDR clones.  
In comparing the tumor immune infiltrate: though the number of CD3+ 
cells/100 mm2 met area was not statistically significantly higher in mice injected with 
VDR-B16BL6 cells (P=0.11, compared to control-B16BL6 cells), there was a trend 
for increased CD3+ immune infiltrate (Supplementary Figure 4).  
Collectively, both models provide causal evidence that elevated vitamin D-
VDR signaling in melanomas cells inhibits Wnt/d-catenin signalling and tumor 
proliferation.
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Discussion 
 
Melanoma is one of the most immunogenic malignancies:  increased lymphocytic 
infiltration in both primaries (37, 38) and metastases (39) is associated with improved 
outcomes (16, 21) and melanoma responses to immune checkpoint blockade are 
high (40, 41). However, dampened immune responses and therapeutic resistance 
attributed to oncogenic pathways such as Wnt/d-catenin signaling (16, 42) mean that 
only 58% of stage IV melanoma patients have significant benefit. Identification of 
factors that boost anti-tumor immunity is required to improve outcomes.  
Low vitamin D levels are associated with thicker, poorer-prognosis primary 
melanomas (11), and lower VDR expression is associated with melanoma 
progression (43, 44) but neither causality nor the mechanistic basis has been 
established. In this report, we demonstrate that vitamin D-VDR signaling is protective 
for melanoma death at least in part through inhibition of Wnt/d-catenin signaling, 
impacting on melanoma proliferation and anti-tumor immune response.  
We report that VDR expression was significantly lower in advanced tumors in the 
LMC primary melanomas. Importantly, high VDR expression was independently 
protective of melanoma death after adjusting for AJCC stage, mitotic rate and TILs. 
Survival benefit was replicated in the TCGA metastatic tumors, highlighting the 
significance of vitamin D-VDR signaling in both primary and metastatic melanoma 
progression. This protective effect of VDR was independent of the expression of 
other NR1L family genes, despite reports of integrated activity between nuclear 
receptors (45). In assessing factors which could control VDR expression, VDR copy 
number was not significantly associated with expression in LMC primaries. However, 
distant metastases (which have worse prognosis) had lower VDR copy number 
compared to regional lymph node metastases in the TCGA, suggesting a 
progression-associated genomic loss of VDR. Low VDR-expressing metastatic 
tumors from TCGA were also more likely to be hypermethylated, consistent with 
previous reports of the epigenetic control of VDR expression (46). Despite the 
progressive deletion of the VDR locus with tumor progression in metastatic disease, 
the data suggest that therapeutic manipulation of vitamin D-VDR signaling could 
have adjuvant therapeutic benefit in primary disease where we saw little evidence of 
VDR deletion.  
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An agnostic correlation analysis revealed that VDR expression was strongly 
positively correlated with immune-related pathways and negatively correlated with 
proliferation-associated pathways in LMC primaries and TCGA metastases. An 
additional sensitivity analyses adjusting for FLG2 expression, produced no significant 
changes in the correlated pathways, indicating that artefact from keratinocyte-rich 
tumor populations was unlikely. VDR expression was higher in ‘brisk’ immune-
infiltrated primaries compared to tumors with no immune infiltrate, which is in 
agreement with a previous report of a smaller immunohistochemical study (43) and 
is an independent validation of the transcriptomic imputation of immune infiltration.  
58% of the genes within reported genomic VDR-binding regions (identified from VDR 
ChIP-Seq data as well as VDR-binding motif) were found to correlate with tumour 
VDR expression in the LMC. This is consistent with direct transcriptional control by 
the VDR transcription factor for a proportion of differentially expressed genes. 
Validation using published prognostic melanoma molecular phenotypes (16, 35) 
revealed that VDR expression was significantly higher in high-immune subtypes 
compared to proliferative subtypes, consistent with the view that the prognostic 
significance of VDR is associated with increased immune and decreased 
proliferative signaling. We also assessed if VDR preferentially correlated with a 
particular immune cell type, which was previously uncharacterised in primary 
melanomas. However, VDR was strongly positively correlated with all imputed 
immune cell scores: we have previously reported simultaneous upregulation of 
adaptive and innate immunity in good prognosis primary melanomas (16). 
Furthermore, the pro-immune effect of vitamin D-VDR signaling was supported by 
strong positive correlation of VDR with genes involved in pathways such as 
extracellular matrix organization, TNFc, NFmB, IFNi and IL-12-mediated signaling.  
In comparing pre-treatment gene expression between responders and non 
responders to immunotherapy, VDR expression was higher in responders to anti-
CTLA4 (FC=1.35), albeit not statistically significant (P=0.12) in this very small data 
set. Though data from these immunotherapy studies did not support VDR expression 
as a biomarker of response, we posit that the data sets available to explore VDR as 
a biomarker were insufficient to properly explore this possibility. 
Wnt/d-catenin signaling was among the top negatively-correlated pathways with 
VDR in the LMC and TCGA melanomas, concordant with reports of vitamin D-VDR-
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mediated inhibition of Wnt/d-catenin signaling in colon cancer (47). We further 
explored this relationship and report that VDR expression was lowest in previosuly 
reported subset of tumors characterized by high-Wnt/d-catenin expression, reduced 
immune infiltrate and high mortality (16). Collectively, our findings support the 
hypothesis that, as in colon cancer, some of the effects of vitamin D-VDR siganling 
in melanoma are mediated by inhibition of Wnt/d-catenin signaling.  
Vitamin D deficiency (<25nmol/L, ~10ng/ml) was associated with worse 
prognosis only in participants with intermediate-VDR expression (albeit the majority). 
Though an agnostic analysis identified no significant transcriptomic differences 
associated with vitamin D in this subgroup, there was some evidence for 
paradoxically reduced expression of immune-associated pathways with higher 
vitamin D levels in a candidate gene expression analysis. The reported associations 
between vitamin D and the immune system are numerous and complex. The findings 
of this study are therefore not inconsistent with the view that vitamin D deficiency 
should be avoided but that high levels would not necessarily be beneficial to all 
patients. 
The lack of a protective effect of higher vitamin D levels in participants with low-
VDR tumors was not unexpected as low receptor expression could preclude effective 
signaling despite ligand sufficiency. A lack of benefit in the high-VDR tumors was 
more surprising and we postulate that this could reflect receptor saturation as 
reported in other NHR family receptors (48) or a ligand-independent effect of VDR, 
which has been described in other cancers (49, 50).  
In functional validation, the observed vitamin D-treatment induced reduction in 
cell proliferation is concordant with previous reports (51). However, the pan-
trasncriptome-based findings that vitamin D treatment of human melanoma cell lines 
promotes VDR expression and inhibition of pro-tumor pathways including the Wnt/d-
catenin pathway, is novel. Furthermore, elevated VDR expression in murine 
melanoma cells decreased their in vivo metastatic potential the expression of key 
Wnt/d-catenin genes, some of which (Dkk1 and Sfrp2) have previously been shown 
to be inhibited by VDR (52), but not in melanomas. Interestingly, the ‘classic’ non-
canonical Wnt ligands Wnt5a, Wnt5b, Wnt10a, Wnt7 and Wnt11 were also 
downregulated by VDR. This finding is of significance because Wnt5a (and some 
other non-canonical Wnt ligands) affect cell motility and invasion and is implicated in 
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worse melanoma prognosis (53). Thus, the findings functionally validate the 
trasncriptome-derived evidence for the inverse association between VDR and Wnt/d-
catenin signalling.  
We report a trend towards increased T cell infiltration of lung metastases 
produced by VDR-expressing B16BL6 melanoma cells, although this did not reach 
statistical significance. Rejection of B16 derivative melanoma cell lines in vivo 
requires both NK and T-cells, and in the pulmonary metastasis model, NK cell 
derived IFN-gamma is important but T-cells also exert important anti-tumour activity 
(32-34, 54-57). The lack of statistically significant reduction in T cell numbers does 
not exclude the possibility that T-cells are more active and/or that NK cell recruitment 
and activity is also modified. To this effect, further analyses of T cell and NK 
recruitment and activity following VDR manipulation is warranted using both the 
subcutaneous and metastatic B16 models.  
 This study reports that vitamin D-VDR signaling bestows a prognostic benefit 
for melanoma patients by inhibiting Wnt/d-catenin signaling and increasing immune 
cell infiltration. These findings also suggest that activating vitamin D-VDR signaling 
has the potential to enhance anti-tumor immunity in an adjuvant setting. Notably, our 
findings suggest that vitamin D deficiency (<25nmol/L) is deleterious for melanoma 
survival rather than that high levels are protective. As melanoma is causally related 
to intense sun burn (58), sun avoidance is frequently recommended to patients in 
follow up. Our data suggest a causal relationship between reduced vitamin D-VDR 
signaling and therefore, as sun exposure is the dominant vitamin D source in most 
populations, simultaneous avoidance of vitamin D deficiency is important health 
advice. 
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Table 1: Association of tumor VDR expression with clinicopathological 
variables and MSS in the 703 LMC participants. BBaseline group used for 
comparison with relevant groups. *Multivariate survival analysis was adjusted for 
AJCC stage, mitotic rate, tumor site and tumor immune infiltrate. MSS: Melanoma 
Specific Survival. Regression Coefficient and P-value from linear regression.  
 
 
 
 
 
 
Univariate Multivariate
Correlation of tumour VDR
expression with
Regression
Coefficient
Std. 
Error
P-value Regression 
Coefficient
Std. 
Error
P-value
Age (per year) -0.005 0.002 0.04 -0.003 0.002 0.14
Sex
FemalesB
Males -0.18 0.06 0.003 -0.09 0.06 0.16
AJCC Stage
Stage IB
Stage II -0.17 0.07 0.012 -0.12 0.07 0.08
Stage III -0.25 0.09 0.009 -0.18 0.09 0.06
Mitotic rate
<1 mitoses/mm2 tumorB
>=1mitoses/mm2 tumor -0.23 0.06 0.0004 -0.20 0.06 0.001
Tumor site 
HeadB
Limbs -0.04 0.10 0.63 -0.11 0.10 0.28
Trunk -0.35 0.10 0.001 -0.36 0.10 0.001
Rare (sun protected sites) -0.44 0.12 0.001 -0.38 0.13 0.003
Table 1
Univariate Multivariate*
Hazard Ratio Std
Error
P-value Hazard Ratio Std
Error
P-value
Effect of tumour VDR expression on 
MSS (per unit expression)
0.75 0.05 0.0001 0.80 0.06 0.008
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Figure legends 
 
Figure 1. Association of VDR expression with copy number and methylation  
A) Correlation of VDR expression with copy number in 276 LMC primaries B) VDR 
expression across categorical copy number estimates from TCGA melanoma 
metastases: -1 (hemizygous deletion), 0 (no change), 1(gain) and 2 (high-level 
amplification) C) VDR median copy number in regional lymph node and distant 
metastases in the TCGA melanomas D) VDR expression in distant, regional lymph 
node metastases and primary tumours in the TCGA dataset E) VDR expression and 
promoter methylation in TCGA metastases.  
 
Figure 2. Whole-transcriptome correlations with VDR expression Volcano plot of 
genes correlated significantly (FDR<0.05) positively (regression coefficient>0.2, 
green dots) and negatively (regression coeffficent <-0.2, red dots) with VDR 
expression in the LMC data; top 25 pathways enriched for each gene list are listed in 
adjoining tables (left for negative, right for positive correlates). FDR: Benjamini-
Hochberg False Discovery Rate. 
 
Figure 3. Association of VDR expression with measures of immune response 
A-B) Comparison of VDR expression between LMC samples classified into Lund and 
TCGA prognostic molecular phenotypes C) Correlation of VDR expression with 
imputed immune cell scores whose correlation coefficient>0.3 D) VDR expression 
across pathologist-graded TILs in the whole tumor FFPE section (P-values from the 
Student t-test) E) Heatmap depicting expression of VDR expression (top bar), 
cytotoxic, T cell and aDC scores, expression of genes coding for checkpoint 
molecules, and expression of Wnt/く-catenin siganling genes across the 6 consensus 
immunome clusters (CICs) reported previously (16).  
 
Figure 4. Vitamin D and VDR subgroup analysis in the Leeds Melanoma Cohort 
dataset  A) prognosis-based stratification of 703 LMC tumors into low-, intermediate- 
and high-VDR tumor groups identified using X-tile B) Kaplan-Meier curves showing 
the differential melanoma-specific survival in those groups C-D) Replication of the 3 
VDR-groups and their association with overall survival in TCGA metastases. E) 
Melanoma-specific survival of 6 vitamin D-VDR subgroups produced by stratification 
of 3 VDR groups by low (<25nmoles/L) or high (>25nmoles/L) serum vitamin D levels 
for winter season. All P-values from the Cox model. 
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Figure 5. Functional validation using in vitro and in vivo models  A) Relative 
proliferation of vitamin D-treated human melanoma cell lines SK-MEL-28 and MeWo: 
24, 48, 72 and 144 hours after treatment, compared to ethanol-treated cells (control). 
B) Pathways enriched in genes upregulated (green bars) or down-regulated (red 
bars) in response to vitamin D treatment of SK-MEL-2828 and MeWo cell lines at 24 
and 48 hours post-treatment C) Pulmonary metastatic loads in control-B16BL6 
(clones C1 and C2) and VDR-B16BL6 (clones V1 and V2) obtained from the tail vein 
metastasis assay. Met count: macroscopic counts of metastases, met area: total 
microscopic metastatic area (om2) in mice lung sections, N-number of mice/group. 
Inset: represenative H&E scanned images of metastases-harboring pulmonary lobes 
D) qRT-PCR array-derived expression of Wnt/く-catenin pathway genes in VDR-
B16BL6 cells (V1 and V2) (FC=fold change relative to control-B16BL6 cells). 
Highlighted in red: genes with a FC<0.5 for both VDR-B16BL6 clones V1 and V2. 
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